[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA95960B - Use of interleukin-12 antagonists in the treatment of autoimmune diseases - Google Patents

Use of interleukin-12 antagonists in the treatment of autoimmune diseases

Info

Publication number
ZA95960B
ZA95960B ZA95960A ZA95960A ZA95960B ZA 95960 B ZA95960 B ZA 95960B ZA 95960 A ZA95960 A ZA 95960A ZA 95960 A ZA95960 A ZA 95960A ZA 95960 B ZA95960 B ZA 95960B
Authority
ZA
South Africa
Prior art keywords
autoimmune
treatment
interleukin
antagonists
autoimmune diseases
Prior art date
Application number
ZA95960A
Other languages
English (en)
Inventor
John P Leonard
Samuel Goldman
Richard O'hara Jr
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22791827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA95960(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of ZA95960B publication Critical patent/ZA95960B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA95960A 1994-03-14 1995-02-07 Use of interleukin-12 antagonists in the treatment of autoimmune diseases ZA95960B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21262994A 1994-03-14 1994-03-14

Publications (1)

Publication Number Publication Date
ZA95960B true ZA95960B (en) 1995-10-10

Family

ID=22791827

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95960A ZA95960B (en) 1994-03-14 1995-02-07 Use of interleukin-12 antagonists in the treatment of autoimmune diseases

Country Status (14)

Country Link
US (1) US6338848B1 (xx)
EP (4) EP2201959A3 (xx)
JP (1) JP3798426B2 (xx)
AT (1) ATE217533T1 (xx)
AU (1) AU689236B2 (xx)
CA (1) CA2185565C (xx)
DE (1) DE69526728T3 (xx)
DK (1) DK0750509T4 (xx)
ES (1) ES2173953T5 (xx)
IL (1) IL112677A (xx)
PT (1) PT750509E (xx)
TW (1) TW400233B (xx)
WO (1) WO1995024918A1 (xx)
ZA (1) ZA95960B (xx)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
TR200002145T2 (tr) * 1998-01-23 2000-11-21 F.Hoffmann-La Roche Ag İnsan IL-12'ye karşı antikorlar
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
DK1137766T3 (da) * 1998-12-09 2006-01-30 Protein Design Labs Inc Anvendelse af IL-12-antistoffer til behandling af psoriasis
JP3419395B2 (ja) 1999-02-10 2003-06-23 三菱ウェルファーマ株式会社 アミド化合物およびその医薬としての用途
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
SK288082B6 (sk) * 1999-03-25 2013-06-03 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12, their use and methods for producing, pharmaceutical composition containing it, nucleic acid and recombinant vector, which they coded, and host cell
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU2005200515B2 (en) * 1999-03-25 2006-07-13 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
JP4676049B2 (ja) * 1999-07-21 2011-04-27 生化学工業株式会社 Ｉｌ−１２産生抑制剤
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
WO2003083071A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
EP1694301A4 (en) 2003-12-02 2009-11-18 Cytimmune Sciences Inc METHOD AND COMPOSITIONS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
NZ582466A (en) 2004-07-30 2011-09-30 Adeza Biomedical Corp Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
AR051805A1 (es) 2004-12-21 2007-02-07 Centocor Inc Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500358A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
CA2675233A1 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
US8557239B2 (en) 2009-09-14 2013-10-15 Abbvie Inc. Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
TWI461210B (zh) 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2341934A4 (en) * 2008-09-30 2012-07-25 Baylor Res Inst PROCESS FOR REDUCING T-HELPER CELLS FOR TREATING AUTOIMMUNE DISEASES
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
PE20121530A1 (es) 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CA2812310A1 (en) 2010-09-28 2012-04-19 Neumedicines, Inc. Uses of il-12 and the il-12 receptor positive cell in tissue repair and regeneration
SG191312A1 (en) 2010-12-21 2013-07-31 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
DK2709651T3 (en) * 2011-05-19 2018-01-08 Univ Rush Medical Center IL-12-P40 MONOMER, MONOCLONAL ANTIBODY AGAINST P40 HOMODIMER, AND A COMBINATION OF THE TWO FOR THE TREATMENT OF AUTO-IMMUNE DISEASE
US20140178335A1 (en) * 2011-07-27 2014-06-26 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
RU2017137740A (ru) 2012-11-01 2019-02-11 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP7468992B2 (ja) 2016-03-29 2024-04-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
CA3113837C (en) 2018-09-24 2022-07-12 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
ATE369383T1 (de) 1989-12-22 2007-08-15 Hoffmann La Roche Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
DE4315127A1 (de) † 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
EP0638644A1 (en) * 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
PL193499B1 (pl) * 1996-02-09 2007-02-28 Abbott Biotech Ltd Izolowane ludzkie przeciwciało, rekombinowane ludzkie przeciwciało, kompozycja farmaceutyczna, sposób hamowania aktywności ludzkiego TNFalfa in vitro, zastosowanie tych izolowanych ludzkich przeciwciał i izolowany kwas nukleinowy
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
NZ337769A (en) * 1997-03-18 2002-09-27 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
TR200002145T2 (tr) * 1998-01-23 2000-11-21 F.Hoffmann-La Roche Ag İnsan IL-12'ye karşı antikorlar
US8700033B2 (en) 2008-08-22 2014-04-15 International Business Machines Corporation Dynamic access to radio networks
CN102377479B (zh) 2010-08-11 2015-01-21 华为技术有限公司 数据同步方法及系统、光网络单元

Also Published As

Publication number Publication date
ES2173953T3 (es) 2002-11-01
EP2311484A1 (en) 2011-04-20
JP3798426B2 (ja) 2006-07-19
TW400233B (en) 2000-08-01
DE69526728T3 (de) 2007-01-04
DE69526728D1 (de) 2002-06-20
EP0750509B2 (en) 2006-06-14
WO1995024918A1 (en) 1995-09-21
DK0750509T3 (da) 2002-07-08
EP0750509A1 (en) 1997-01-02
AU689236B2 (en) 1998-03-26
AU1974995A (en) 1995-10-03
EP2201959A2 (en) 2010-06-30
CA2185565A1 (en) 1995-09-21
PT750509E (pt) 2002-08-30
EP2201959A3 (en) 2011-03-16
ES2173953T5 (es) 2007-03-01
CA2185565C (en) 2009-02-03
JPH09510444A (ja) 1997-10-21
EP1179348A2 (en) 2002-02-13
IL112677A (en) 2000-01-31
EP0750509B1 (en) 2002-05-15
EP1179348A3 (en) 2003-12-03
US6338848B1 (en) 2002-01-15
ATE217533T1 (de) 2002-06-15
IL112677A0 (en) 1995-05-26
DK0750509T4 (da) 2006-10-16
DE69526728T2 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
ZA95960B (en) Use of interleukin-12 antagonists in the treatment of autoimmune diseases
Becker Affective disorders.
ATE411029T1 (de) Estrogene als antimitotika
UA37244C2 (uk) Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі
WO1994007535A3 (en) Labelled interleukin-8 and medical uses thereof
GR3019343T3 (en) Latency associated peptide and uses therefor
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
Jacoby et al. Patterns of spontaneous cortisol and growth hormone secretion in rhesus monkeys during the sleep-waking cycle
DK399288A (da) Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion
HUT59600A (en) Process for producing pharmaceutical compositions containing 5-methyl-isoxazoe-4-carboxylik-anilides or alpha-/2-hydroxy-ethylidene/-alpha-cyano-acetic-anilides for treating eye-diseases
FR2707131B1 (fr) Dispositif électronique comprenant un régulateur de charge interne pour contrôler l'application d'un courant de charge et procédé qui lui est associé.
Kemp Model-based monitoring of human sleep stages
Kirk et al. A brief inservice training strategy to increase levels of empathy of psychiatric nursing personnel.
EP0431188A4 (en) Method of modifying medical material based on lactate polymer
FR2663076B1 (fr) Methode et dispositif perfectionnes pour ameliorer les diagraphies de production d'un puits non eruptif active.
Hawkins I recently saw a patient with a most unusual inflammatory arthritis of the knee. Deliberate self-harm was suggested by the general practitioner. How should I evaluate this possibility, and if necessary treat the problem?
Finnerty-Fried Adapting rehabilitation counseling for older persons.
Himle et al. Recent research on social support and burnout: Implications for behavior therapy.
Silverman et al. Characteristics of re-referred families in a child abuse program.
Suarez et al. Abetalipoproteinemia associated with hepatic and atypical neurological disorders.
Ivashov et al. The method of personal communicative sets study
Shimoda et al. Follow-up Study of Splinting for Pollux Rigidus
NAGATA et al. Preliminary study on the influence of horizontal sway in a low frequency range by a linear accelerator
Kochansky Lidocaine anesthesia for attenuation of stress responses in cardiovascular surgery: An old technique revisited.
Sakamoto et al. A Case Report of Multiple Tendon Xanthomas